Oventus Medical Ltd (ASX:OVN) is pleased to announce the Canadian launch of the O2Vent(R) Optima device which treats both the potentially fatal condition, obstructive sleep apnoea and snoring. The device launch in Canada follows the successful completion of a controlled market release, with early results demonstrating strong patient acceptance.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent(TM) is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com
Oventus Medical Ltd (ASX:OVN) is pleased to announce the launch of the O2Vent(R) Optima device in Australia, an important addition to the Company's sleep treatment platform.
Oventus Medical Ltd (ASX:OVN) provides the Company's 2018 AGM Presentation.
Oventus Medical Ltd (ASX:OVN) New Clinical Trial Data Demonstrates Sleep Treatment Platform Delivers Significantly Improved Treatment Outcomes for OSA Sufferers
Oventus Medical Ltd (ASX:OVN) is pleased to announce that new clinical data from four separate studies on its Sleep Treatment Platform will be presented at Sleep DownUnder, the 30th annual meeting of sleep specialists, taking place in Brisbane between 17th -20th October.
Oventus Medical Ltd (ASX:OVN) Appoints Medical Technology Advisory Board to Guide Commercialisation of Sleep Treatment Platform
Oventus Medical Ltd (ASX:OVN) is pleased to announce the appointment of a Medical Technology Advisory Board of international sleep experts to help guide the development and commercialisation of the Company's Sleep Treatment Platform.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 30 June 2018 (Q4 FY2018) and is pleased to provide a review of progress made during the quarter.
Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.
Oventus Medical Ltd (ASX:OVN) Innovators in Sleep Apnoea Treatment Presentation for Thorney Investment Forum
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
Oventus Medical Ltd (ASX:OVN) is pleased to announce positive interim data being presented today in a lecture at Macquarie University on a group of hard-to-treat obstructive sleep apnoea patients, who were studied in a sub-group as part of the ongoing "NeuRA Sydney study".
Oventus Medical Ltd (ASX:OVN) is pleased to announce the results of the OVEN-003 clinical trial study being conducted in Brisbane by the company, a randomised controlled clinical trial examining the treatment outcomes of oral appliance therapy with and without 'Oventus Airway Technology'.